A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

The incidence of HER2 somatic mutations in breast cancer is about 2–4%, mainly occurring in the HR+/HER2- subtype. Preclinical studies suggest that HER2 mutations can lead to constitutive HER2 activation, but effective treatment options for the clinical management of patients with HER2 mutations rem...

Descrizione completa

Dettagli Bibliografici
Autori principali: Jing Ma, Xuelu Li, Qianran Zhang, Ning Li, Siwen Sun, Shanshan Zhao, Zuowei Zhao, Man Li
Natura: Articolo
Lingua:English
Pubblicazione: Elsevier 2022-07-01
Serie:Translational Oncology
Soggetti:
Accesso online:http://www.sciencedirect.com/science/article/pii/S1936523322001036